Literature DB >> 18004235

Acute respiratory disease associated with adenovirus serotype 14--four states, 2006-2007.

.   

Abstract

Adenovirus serotype 14 (Ad14) is a rarely reported but emerging serotype of adenovirus that can cause severe and sometimes fatal respiratory illness in patients of all ages, including healthy young adults. In May 2006, an infant in New York aged 12 days died from respiratory illness caused by Ad14. During March-June 2007, a total of 140 additional cases of confirmed Ad14 respiratory illness were identified in clusters of patients in Oregon, Washington, and Texas. Fifty-three (38%) of these patients were hospitalized, including 24 (17%) who were admitted to intensive care units (ICUs); nine (5%) patients died. Ad14 isolates from all four states were identical by sequence data from the full hexon and fiber genes. However, the isolates were distinct from the Ad14 reference strain from 1955, suggesting the emergence and spread of a new Ad14 variant in the United States. No epidemiologic evidence of direct transmission linking the New York case or any of the clusters was identified. This report summarizes the investigation of these Ad14 cases by state and city health authorities, the U.S. Air Force, and CDC. State and local public health departments should be alert to the possibility of outbreaks caused by Ad14.

Entities:  

Mesh:

Year:  2007        PMID: 18004235

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  58 in total

1.  Adenovirus microsatellite reveals dynamics of transmission during a recent epidemic of human adenovirus serotype 14 infection.

Authors:  Huo-Shu H Houng; Lisa Lott; Heping Gong; Robert A Kuschner; Julia A Lynch; David Metzgar
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

2.  UV disinfection of adenoviruses: molecular indications of DNA damage efficiency.

Authors:  Anne C Eischeid; Joel N Meyer; Karl G Linden
Journal:  Appl Environ Microbiol       Date:  2008-10-31       Impact factor: 4.792

3.  Respiratory failure presenting in H1N1 influenza with Legionnaires disease: two case reports.

Authors:  Michele Iannuzzi; Edoardo De Robertis; Ornella Piazza; Fabio Rispoli; Giuseppe Servillo; Rosalba Tufano
Journal:  J Med Case Rep       Date:  2011-10-21

Review 4.  Emerging viral diseases.

Authors:  Andrew Pekosz; Gregory E Glass
Journal:  Md Med       Date:  2008

5.  Quantitative real-time PCR assay panel for detection and type-specific identification of epidemic respiratory human adenoviruses.

Authors:  Xiaoyan Lu; Elizabeth Trujillo-Lopez; Lisa Lott; Dean D Erdman
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

6.  Evaluation of multiplex type-specific real-time PCR assays using the LightCycler and joint biological agent identification and diagnostic system platforms for detection and quantitation of adult human respiratory adenoviruses.

Authors:  David Metzgar; Carl Gibbins; N Ryan Hudson; Morris S Jones
Journal:  J Clin Microbiol       Date:  2010-01-06       Impact factor: 5.948

7.  Management of Acute Respiratory Failure in Patients With Hematological Malignancy.

Authors:  Rakesh Vadde; Stephen M Pastores
Journal:  J Intensive Care Med       Date:  2016-07-07       Impact factor: 3.510

8.  Evaluation and validation of a real-time PCR assay for detection and quantitation of human adenovirus 14 from clinical samples.

Authors:  David Metzgar; Greg Skochko; Carl Gibbins; Nolan Hudson; Lisa Lott; Morris S Jones
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

9.  Characterization of culture-positive adenovirus serotypes from respiratory specimens in Toronto, Ontario, Canada: September 2007-June 2008.

Authors:  Rani Yeung; AliReza Eshaghi; Ernesto Lombos; Joanne Blair; Tony Mazzulli; Laura Burton; Steven J Drews
Journal:  Virol J       Date:  2009-01-26       Impact factor: 4.099

10.  Human adenovirus 14a: a new epidemic threat.

Authors:  Gregory C Gray; Margaret L Chorazy
Journal:  J Infect Dis       Date:  2009-05-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.